Alexion Pharmaceuticals, Inc. (ALXN) Shares Bought by State of Tennessee Treasury Department

State of Tennessee Treasury Department grew its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 69.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 595,919 shares of the biopharmaceutical company’s stock after acquiring an additional 244,916 shares during the quarter. State of Tennessee Treasury Department’s holdings in Alexion Pharmaceuticals were worth $71,266,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Ameriprise Financial Inc. lifted its position in shares of Alexion Pharmaceuticals by 3.5% in the third quarter. Ameriprise Financial Inc. now owns 6,390,301 shares of the biopharmaceutical company’s stock valued at $896,491,000 after acquiring an additional 215,005 shares in the last quarter. Jennison Associates LLC lifted its position in shares of Alexion Pharmaceuticals by 720.0% in the third quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock valued at $748,116,000 after acquiring an additional 4,682,336 shares in the last quarter. UBS Asset Management Americas Inc. lifted its position in shares of Alexion Pharmaceuticals by 10.3% in the fourth quarter. UBS Asset Management Americas Inc. now owns 1,871,548 shares of the biopharmaceutical company’s stock valued at $223,818,000 after acquiring an additional 174,606 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of Alexion Pharmaceuticals by 32.7% in the third quarter. Wells Fargo & Company MN now owns 1,558,531 shares of the biopharmaceutical company’s stock valued at $218,647,000 after acquiring an additional 383,713 shares in the last quarter. Finally, Bank of Montreal Can lifted its position in shares of Alexion Pharmaceuticals by 21.4% in the fourth quarter. Bank of Montreal Can now owns 1,521,834 shares of the biopharmaceutical company’s stock valued at $181,998,000 after acquiring an additional 268,053 shares in the last quarter. Institutional investors and hedge funds own 95.38% of the company’s stock.

In other Alexion Pharmaceuticals news, CEO Ludwig Hantson sold 2,553 shares of Alexion Pharmaceuticals stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $121.63, for a total value of $310,521.39. Following the sale, the chief executive officer now owns 36,172 shares in the company, valued at $4,399,600.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Heidi L. Wagner sold 1,774 shares of Alexion Pharmaceuticals stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $116.31, for a total value of $206,333.94. Following the completion of the sale, the senior vice president now owns 47,212 shares in the company, valued at approximately $5,491,227.72. The disclosure for this sale can be found here. Insiders sold 28,930 shares of company stock worth $3,378,199 in the last 90 days. Company insiders own 4.35% of the company’s stock.

Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) opened at $118.85 on Wednesday. Alexion Pharmaceuticals, Inc. has a 1 year low of $96.18 and a 1 year high of $149.34. The company has a market capitalization of $26,350.00, a P/E ratio of 54.77, a P/E/G ratio of 1.12 and a beta of 1.16. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.62 and a current ratio of 3.10.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 EPS for the quarter, beating the Zacks’ consensus estimate of $1.09 by $0.39. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. The company had revenue of $909.70 million for the quarter, compared to the consensus estimate of $880.38 million. During the same quarter in the previous year, the business earned $1.26 earnings per share. The company’s revenue for the quarter was up 9.5% on a year-over-year basis. analysts forecast that Alexion Pharmaceuticals, Inc. will post 6.12 EPS for the current year.

Several research firms have recently weighed in on ALXN. Evercore ISI upgraded Alexion Pharmaceuticals from an “in-line” rating to an “outperform” rating in a research report on Monday, February 5th. Citigroup decreased their target price on Alexion Pharmaceuticals from $173.00 to $170.00 and set a “buy” rating on the stock in a research report on Friday, February 9th. Leerink Swann decreased their target price on Alexion Pharmaceuticals from $166.00 to $153.00 and set an “outperform” rating on the stock in a research report on Friday, February 9th. BMO Capital Markets raised their target price on Alexion Pharmaceuticals from $177.00 to $180.00 and gave the company an “outperform” rating in a research report on Friday, February 9th. Finally, SunTrust Banks set a $172.00 target price on Alexion Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, February 12th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and twenty-one have issued a buy rating to the company. Alexion Pharmaceuticals presently has an average rating of “Buy” and an average target price of $152.77.

ILLEGAL ACTIVITY NOTICE: “Alexion Pharmaceuticals, Inc. (ALXN) Shares Bought by State of Tennessee Treasury Department” was reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.thelincolnianonline.com/2018/02/21/alexion-pharmaceuticals-inc-alxn-shares-bought-by-state-of-tennessee-treasury-department.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply